J

Jazz Pharmaceuticals plc

D
JAZZ
USD
7.635
(6.8528%)
Market Closed
52,862.00
Volume
20.184
EPS
-
Div Yield
20.178
P/E
7,351,755,365.50
Market Cap
Today
6.7713%
1 Week
8.208%
1 Month
9.734%
6 Months
7.030%
12 Months
-10.931%
Year To Date
-3.196%
All Time
0%

Title:
Jazz Pharmaceuticals plc

Sector:
Healthcare
Industry:
Biotechnology
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Do you need help or have a question?